Pharmaceutical company Galderma has revealed results from its two phase IIIb trials investigating relabotulinumtoxinA for the treatment of glabellar lines and lateral canthal lines. The first phase IIIb, randomised, double-blind,
Aesthetic manufacturer Croma-Pharma has announced the national approval of its new botulinum toxin in the UK.
As of January 25, aesthetic manufacturer Croma-Pharma has confirmed completion of the decentralised procedure for its new botulinum toxin.
Pharmaceutical company Galderma has confirmed the first ready-to-use liquid neuromodulator has completed its European decentralised trial in Europe.
Biopharmaceutical company Hugel America and aesthetic manufacturer Croma-Pharma has unveiled that the US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for letibotulinumtoxinA as a treatment for glabellar lines.
Global pharmaceutical company Galderma has received top-line results for its phase 2 study in the US on the efficacy and safety of a single dose of abobotulinumtoxinA versus placebo for the treatment of moderate to severe glabellar lines.
Research published in Scientific Reports journal has suggested that botulinum toxin (BoNT-A) could be used as an effective treatment for patients with depression.
Pharmaceutical company Croma Pharma has submitted its botulinum toxin drug file to the German Federal Institute for Drugs and Medical Devices (BfArM), for approval for the treatment of glabellar lines in the EU.
Global pharmaceutical company Galderma’s liquid formulation of botulinum toxin type A has achieved positive results for the treatment of glabellar lines in a phase 2 clinical trial.
On June 17, more than 250 medical professionals tuned in to the second webinar hosted by Aesthetics and supported by Galderma UK.
We bring you the most up-to-date information for the Aesthetics community across a variety of media, including; news, webinars, podcasts, the Journal, reports, interviews and more!
aesthetics Journal
The Aesthetics Journal is the leading monthly publication for the medical aesthetics specialty. It is peer reviewed and spans an incredible volume of topics. Become a member today to receive the monthly print and digital Journal.
0203 096 1228
2nd Floor, Regal House, 70 London Road
Twickenham TW1 3QS, United Kingdom
© 2023 Easyfairs UK Ltd | Registered in England No. 05067979
